Entropy Technologies LP Sells 5,408 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Entropy Technologies LP decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 51.3% during the third quarter, HoldingsChannel reports. The firm owned 5,125 shares of the medical research company’s stock after selling 5,408 shares during the period. Entropy Technologies LP’s holdings in Charles River Laboratories International were worth $1,009,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CRL. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after buying an additional 57 shares during the period. Wolff Wiese Magana LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $32,000. Assetmark Inc. raised its position in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International during the 1st quarter worth $41,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 193 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $206.54 on Thursday. The company has a 50 day simple moving average of $195.14 and a two-hundred day simple moving average of $207.90. The stock has a market cap of $10.56 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 5.57 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12 month low of $174.92 and a 12 month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.72 earnings per share. As a group, analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Charles River Laboratories International announced that its board has initiated a stock repurchase program on Wednesday, August 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 9.6% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Several analysts have commented on CRL shares. TD Cowen increased their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday. Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their target price for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Baird R W lowered Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, UBS Group boosted their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $217.54.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).